EDIM® Technology

INNOVATION IN DIAGNOSTICS


EDIM® Technology

PanTum® Detect is a tumor screening blood test which detects any solid tumor, at any stage. This test is IVD CE certified and is based on Epitope Detection In Monocytes (EDIM®) technology. Activated monocytes (macrophages) phagocytose unwanted cells/cell fragments from the whole body including solid tumor cells. As they return to the blood, macrophages can be used for non-invasive detection of two enzyme biomarkers (Apo10 & TKTL1). EDIM® is a new technology which utilises our innate immune system to detect the presence of two enzyme biomarkers Apo10 & TKTL1 and thus achieve significantly better results in terms of accuracy as measured by Sensitivity & Specificity.

Flow cytometry analysis of a blood sample enables the detection of macrophages and phagocytosed intracellular enzyme biomarkers. In order to establish a pan-tumor blood test, two enzyme biomarkers (Apo10 & TKTL1) for two fundamental biophysical mechanisms have been exploited. Numerous studies have shown that these enzyme biomarkers project multiple different tumor entities, because they represent biophysical mechanisms in tumor cells. The DNaseX/Apo10 protein epitope is a characteristic of tumor cells with abnormal apoptosis and proliferation. Transketolase-like 1 (TKTL1) is a marker for an anaerobic glucose metabolism (Warburg effect), which is concomitant with invasive growth/metastasis and resistant to radical and apoptosis inducing therapies.

Pantum® Detect coupled with Pathology and Imaging diagnostics (Cancers-Scan) will not only help reduce cancer related deaths via a regular screening check for healthy people, but will also massively reduce the cost and strain on the Healthcare System with regards to cancer treatment in late stages and relapse for cancer survivors. It is truly a revolution in cancer care. The test has already proven its capabilities with over 250,000 blood samples analysed across 40 tumor entities.

EDIM® technology along with flow cytometric analysis of human blood determines a score for each enzyme biomarkers and both scores are then summed up to form the PanTum® Detect score. Studies have shown that the summed-up score results in best performance data.

https://www.medidect.com/wp-content/uploads/2022/12/zyagnum-ag-grafic-edim-2-e1657021888989.jpg

Enzyme biomarkers in use

Apo10

The DNaseX/Apo10 protein epitope is a characteristic of tumour cells with abnormal apoptosis and proliferation.

TKTL1

Transketolase-like 1 (TKTL1) is a marker for aggressiveness of a tumor. TKTL1 regulates aerobic glycolysis which is fermentation of glucose in the presence of oxygen (Warburg effect), which is concomitant with invasive growth/metastasis and resistant to radical and apoptosis inducing therapies.

Biomarkers in Use

https://www.medidect.com/wp-content/uploads/2022/12/zyagnum-ag-grafic-edim-2-e1657021888989.jpg

Apo10

Elevated concentrations of DNaseX (Apo10) enzyme shows a disruption of programmed cell death (Apoptosis). It provides indication of tumor proliferation.

TKTL1

Transketolase-like 1 (TKTL1) is a marker for aggressiveness of a tumor. TKTL1 regulates aerobic glycolysis which is fermentation of glucose in the presence of oxygen (Warburg effect), which is concomitant with invasive growth/metastasis and resistant to radical and apoptosis inducing therapies.

Check eligibility for PanTum® Detect
blood test
Asymptomatic Healthy individuals with intact immune system
  • Should not be undergoing cancer treatment or immunosuppressants drug
  • Should not be under influence of febrile illness, Inflammation, COVID, surgery or severe trauma in 8 weeks prior to blood sample draw
  • No vaccination in the last 4 weeks prior to blood sample draw.
For assistance from customer service executive, please fill form and submit
Thank You. We will contact you as soon as possible.